Danica Pension Livsforsikringsaktieselskab Buys New Holdings in Avantor, Inc. $AVTR

Danica Pension Livsforsikringsaktieselskab purchased a new position in Avantor, Inc. (NYSE:AVTR) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 63,072 shares of the company’s stock, valued at approximately $624,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AVTR. EverSource Wealth Advisors LLC raised its position in shares of Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after buying an additional 1,189 shares during the last quarter. Private Trust Co. NA boosted its position in shares of Avantor by 46.2% during the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after acquiring an additional 875 shares during the last quarter. Strategic Wealth Investment Group LLC bought a new position in shares of Avantor during the second quarter worth $32,000. Los Angeles Capital Management LLC bought a new position in shares of Avantor during the fourth quarter worth $32,000. Finally, Osaic Holdings Inc. grew its stake in Avantor by 60.9% during the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after acquiring an additional 1,064 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Morgan Stanley boosted their price target on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. TD Cowen restated a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $13.00 target price on shares of Avantor in a report on Thursday, July 30th. UBS Group set a $8.00 target price on Avantor in a research report on Wednesday, June 24th. Finally, Barclays increased their price target on Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Avantor Stock Performance

Shares of NYSE:AVTR opened at $13.97 on Thursday. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93. The stock has a market capitalization of $9.45 billion, a P/E ratio of -16.63, a PEG ratio of 10.04 and a beta of 0.89. The firm has a fifty day simple moving average of $11.44 and a two-hundred day simple moving average of $9.59. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. During the same period in the previous year, the firm posted $0.24 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts expect that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.